Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin

被引：13

作者：

Boucly, Athenais ^{[1
,2
,3
]}

O'Connell, Caroline ^{[1
,2
,3
]}

Savale, Laurent ^{[1
,2
,3
]}

O'Callaghan, Dermot S. ^{[4
]}

Jais, Xavier ^{[1
,3
]}

Montani, David ^{[1
,2
,3
]}

Humbert, Marc ^{[1
,2
,3
]}

Simonneau, Gerald ^{[1
,2
,3
]}

Sitbon, Olivier ^{[1
,2
,3
]}

机构：

[1] DHU TORINO, Ctr Reference Hypertens Pulm Severe, Serv Pneumol & Soins Intensifs, AP HP,Hop Bicetre, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France

[2] Univ Paris 11, Fac Med, F-94270 Le Kremlin Bicetre, France

[3] INSERM, U999, HTAP Physiopathol & Innovat Therapeut, F-92350 Le Plessis Robinson, France

[4] Mater Misericordiae Univ Hosp, Dept Resp Med, Dublin, Ireland

来源：

PRESSE MEDICALE | 2016年 / 45卷 / 01期

关键词：

BLOOD-STREAM INFECTIONS; CATHETER-RELATED COMPLICATIONS; OPEN-LABEL; EPOPROSTENOL PROSTACYCLIN; PROSTANOID THERAPY; IV TREPROSTINIL; GUIDELINES; PATHOGENESIS; TRANSITION; PREVENTION;

D O I：

10.1016/j.lpm.2015.10.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Intravenous prostacyclins are a valuable treatment for patients with severe pulmonary arterial hypertension, leading to improved exercise capacity, haemodynamics, quality of life and survival. Unfortunately, due to the short half- life of these drugs, they need to be administered continuously through central venous catheters. Despite aseptic technique, regular dressing changes, tunneled central venous catheters and patient education, patients are exposed to central venous catheter associated infections. These infections cause significant morbidity and mortality. The clinical presentation, microbiology, consequences and management of these central venous catheter associated infections in pulmonary arterial hypertension patients treated with intravenous prostacyclins are discussed.

引用

页码：20 / 28

页数：9

共 40 条

[1] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[2]

Barst R., 2007, Morbidity and Mortality Weekly Report, V56, P170

[3] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[4] Mechanical and infective central venous catheter-related complications: A prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies [J].

Biagi, E ;

Arrigo, C ;

DellOrto, MG ;

Balduzzi, A ;

Pezzini, C ;

Rovelli, A ;

Masera, G ;

Silvestri, D ;

Uderzo, C .

SUPPORTIVE CARE IN CANCER, 1997, 5 (03) :228-233

[5] Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study [J].

Chin, Kelly M. ;

Badesch, David B. ;

Robbins, Ivan M. ;

Tapson, Victor F. ;

Palevsky, Harold I. ;

Kim, Nick H. ;

Kawut, Steven M. ;

Frost, Adaani ;

Benton, Wade W. ;

Lemarie, Jean-Christophe ;

Bodin, Frederic ;

Rubin, Lewis J. ;

McLaughlin, Vallerie .

AMERICAN HEART JOURNAL, 2014, 167 (02) :218-+

[6] Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension [J].

Doran, A. K. ;

Ivy, D. D. ;

Barst, R. J. ;

Hill, N. ;

Murali, S. ;

Benza, R. L. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 :5-9

[7] Novel approach to investigate a source of microbial contamination of central venous catheters [J].

Elliott, TSJ ;

Moss, HA ;

Tebbs, SE ;

Wilson, IC ;

Bonser, RS ;

Graham, TR ;

Burke, LP ;

Faroqui, MH .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (03) :210-213

[8] Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study [J].

Frantz, Robert P. ;

Schilz, Robert J. ;

Chakinala, Murali M. ;

Badesch, David B. ;

Frost, Adaani E. ;

McLaughlin, Vallerie V. ;

Barst, Robyn J. ;

Rosenberg, Daniel M. ;

Miller, Dave P. ;

Hartline, Brian K. ;

Benton, Wade W. ;

Farber, Harrison W. .

CHEST, 2015, 147 (02) :484-494

[9] Guidelines for the diagnosis and treatment of pulmonary hypertension [J].

Galie, Nazzareno ;

Hoeper, Marius M. ;

Humbert, Marc ;

Torbicki, Adam ;

Vachiery, Jean-Luc ;

Albert Barbera, Joan ;

Beghetti, Maurice ;

Corris, Paul ;

Gaine, Sean ;

Gibbs, J. Simon ;

Angel Gomez-Sanchez, Miguel ;

Jondeau, Guillaume ;

Klepetko, Walter ;

Opitz, Christian ;

Peacock, Andrew ;

Rubin, Lewis ;

Zellweger, Michael ;

Simonneau, Gerald .

EUROPEAN HEART JOURNAL, 2009, 30 (20) :2493-2537

[10] PATHOGENESIS OF INFECTIONS RELATED TO INTRAVASCULAR CATHETERIZATION [J].

GOLDMANN, DA ;

PIER, GB .

CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (02) :176-192

← 1 2 3 4 →